# Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

> **NCT05126303** · PHASE2 · TERMINATED · sponsor: **Guard Therapeutics AB** · enrollment: 177 (actual)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **DRUG:** RMC-035
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05126303
- **Lead sponsor:** Guard Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-31
- **Primary completion:** 2023-04-15
- **Final completion:** 2023-07-12
- **Target enrollment:** 177 (ACTUAL)
- **Why stopped:** Enrollment discontinued following DMC recommendation based on futility with regards to primary endpoint
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05126303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05126303, "Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05126303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*